Coulter & Idec

The choice between yttrium and iodine

The Coulter view

While Coulter believes there is a place for yttrium in cancer therapy, potentially against solid tumors, the company considers iodine to be a better choice for lymphomas because penetration of the antibody into tissues isn't an issue and myelosuppression is a significant risk with yttrium.

Clinical issues

- Can tailor dose to individual patient. Because iodine is a gamma emitter, patient-specific elimination rates, which vary significantly, can be calculated from gamma camera scans. Because scans are not possible with beta emitters, this type of patient-specific dosing can't be carried out directly with yttrium.